Unilife Corp

Unilife — Investor Presentation (October 2014)

21 slides from Unilife's investor presentation, Oct 6, 2014

  1. Slide 1: Unilife Leadership for Wearable Injectors

    Exhibit 99.1 Unilife Leadership for Wearable Injectors October 6, 2014

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements Thispresentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our manag

  3. Slide 3: A Strategic Partner for Injectable Therapies

    A Strategic Partner for Injectable Therapies Long-Term Partnerships to Create Customer Value A Broad, Market-Driven Portfolio for all Injectable Therapies Innovation within a Standard Footprint to Minimize Risk Delivering High-Quality Products in Accelerated Timelines Dedicated, Responsive Teams wit

  4. Slide 4: Highlights

    Highlights • Unilife signs second long-term supply agreement for wearable injectors • To be sole provider of wearable injectors to Sanofi for all of its applicable large volume drugs, excluding insulins, for a minimum 15 years • Revenue to begin this fiscal year via an upfront payment customization

  5. Slide 5: A Broad, Flexible Portfolio for Injectable Biologics

    A Broad, Flexible Portfolio for Injectable Biologics Prefilled Reconstitution Auto- Wearable Ocular Novel Syringes Systems Injectors Injectors Systems Systems For all prefilled For all liquid-liquid or For all handheld For all wearable For accurate, For when drugs, vaccines liquid dry drug self-inje

  6. Slide 6: Multiple Platforms. Endless Product Configurations.

    Multiple Platforms. Endless Product Configurations. Unifill® Unifill Finesse™ Unifill Select™ Unifill Allure ™ Unifill Nexus™ AutoMix Presto™ EZMix Genesis™ EZMix Engage™ EZMix Prodigy™ RITA™ LISA™ Precision-Therapy™ Flex-Therapy™ Ocu-mix™ Depot-ject™ Ocu-ject™ Micro-ject™

  7. Slide 7: Market Trends for Self-Injection of Large Dose Volumes

    Market Trends for Self-Injection of Large Dose Volumes Biologics Self- Injection • 1,000+ biologics in development • Half of healthcare outside of • Complex molecules with well-defined patient healthcare facilities in 10 years* populations • Many too viscous for handheld devices Device-Led Benefits

  8. Slide 8: Wearable Injectors

    Wearable Injectors Disposable delivery systems for the self- injection of large dose volume drugs • Dose volumes from 2mL to 10mL • Primarily subcutaneous admin. route • Typical injection frequencies from every week to every month • Pre-configured for injection periods from seconds to hours • Bolus,

  9. Slide 9: Generating Patient Outcomes. Reducing Healthcare Costs.

    Generating Patient Outcomes. Reducing Healthcare Costs. • Wearable injectors are an • Patient non-compliance is a key enabling technology that can healthcare challenge, affecting help redefine treatment in many patient health and creating therapy areas by empowering healthcare system inefficiencies

  10. Slide 10: Optimizing User Preference. Enhancing Brand Differentiation.

    Optimizing User Preference. Enhancing Brand Differentiation. • Healthcare markets and regulatory agencies increasingly desire patient-centric therapies that generate value and health outcomes for patients and healthcare systems. • Delivery systems are increasingly important in the approval and lifec

  11. Slide 11: Wearable Injectors: 188% CAGR to $8B Market by 2025

    Wearable Injectors: 188% CAGR to $8B Market by 2025 Device Sales by Revenue ($ MM) Device Sales by Units (MM) $10,000 400 $8,000 300 $6,000 200 $4,000 100 $2,000 $- 0 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Drugs in Wearable Injec

  12. Slide 12: Serving Multiple Therapy Areas and Drug Categories

    Serving Multiple Therapy Areas and Drug Categories Wearable Injectors have broad pharmaceutical application Anti-thrombotics Genetic disorders mAbs Auto-Immune Recombinant proteins Infectious diseases Blood Disorders Interferons Muscoloskeletal Peptides Oncology Neurologic Antisenses Cardiovascular

  13. Slide 13: Unilife's Wearable Injector Platform

    Unilife’s Wearable Injector Platform Pre-filled. Pre-assembled. Ready for injection. Precision-Therapy ™ Flex-Therapy ™ For long-duration therapies that require For long-duration therapies that require delivery of a single, large-volume dose. delivery of a large-volume dose at a predefined rate prof

  14. Slide 14: What sets Unilife's technology apart

    What sets Unilife’s technology apart: Simple to Use o Pre-filled and pre-assembled o Three intuitive steps of use (Peel, Stick and Click™) o Audible, tactile and visual indicators o Multiple safety features Simple to Customize o Highly customizable design and function o Option for Bluetooth connecti

  15. Slide 15: Drug-Device Regulatory Pathways

    Drug-Device Regulatory Pathways Combination Product (A)NDA Submission Delivery U.S System • Regulated under Drug Product Master File/510(k) CDER CDRH • [References Delivery System Filing] Pharmaceutical Unilife Development Pharmaceutical Partner and Submission Partner Submission Development Combinat

  16. Slide 16: Unilife's Leading Technical Capabilities

    Unilife’s Leading Technical Capabilities Rapid Product Commercialization Streamlined Production Scalability Dedicated teams of Technical Experts State-of-the-art U.S. Facilities IP Portfolio with Freedom to Operate Assurance and Flexibility of Supply

  17. Slide 17: Unilife Customers and Pipeline for Wearable Injectors

    Unilife Customers and Pipeline for Wearable Injectors Typically A multitude of portfolios with Commercial other target multiple large Pipeline programs at dose volume various stages drugs Revenue from Multiple programs initial phases Unilife Customer Customer of underway or to Relationships Programs

  18. Slide 18: Today's 15-Year Agreement with Sanofi

    Today’s 15-Year Agreement with Sanofi 15-Year Master Services and Commercial Supply Agreement Unilife to be sole provider of wearable injectors for use with all of Sanofi’s applicable large dose volume drugs, excluding insulin Sanofi’s portfolio includes several mAbs and other biologics Such drugs o

  19. Slide 19: Revenue Streams During Agreement Period

    Revenue Streams During Agreement Period Upfront payment Unilife receives an upfront payment upon the signing of this agreement Customization payments Unilife to receive milestone-based payments from Sanofi to customize its wearable injectors to requirements of each applicable drug / indication Each

  20. Slide 20: A Demonstration of Unilife's Business Model

    A Demonstration of Unilife’s Business Model Long-term partnerships for drug-device combination products • Differentiated devices become part of the regulatory drug label • Multiple target drugs, indications and therapy areas • Each relationship can expand with incremental agreements for other produc

  21. Slide 21: Questions

    Questions Confidential-Unilife Corporation

Unilife — Investor Presentation (October 2014) on 6ix